Peripheral Neuropathy Trial, Recruiting NCT05009394 Sponsor: Prometei Pain Rehabilitation Center Condition: Peripheral Neuropathy
Back to Peripheral Neuropathy

Peripheral Neuropathy Trial, Recruiting

NCT05009394
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The person has had a major limb amputation.
  • The person is 18 years of age or older at the time of signing the consent form.
  • The person is considered healthy enough to undergo surgery, in the treating doctor's opinion.
  • At least one year has passed since the person's most recent amputation.
  • The person experiences residual limb pain (pain in the remaining part of the limb) that rates 4 or higher on average on a 0–10 pain scale, measured after a baseline observation period.
  • If the person has been prescribed medication for pain, the dose must have remained unchanged for at least one month before the screening visit.
  • If the person has been receiving non-medication pain treatments — such as spinal cord stimulation, electrical nerve stimulation, or mirror therapy — those treatments must have ended at least one month before the screening visit.
  • The person has had a stable, well-fitted prosthetic limb for at least one month before the screening visit.
  • The person has a sufficient understanding of the language used in the study assessments, in the treating doctor's opinion.

Who may not be able to join:

  • The person has a neurological condition or other health condition that affects how nerves heal or regenerate in the area to be treated.
  • The person has an active infection in the remaining part of the amputated limb.
  • The person has previously had specific nerve-related surgeries (called RPNI or TMR) on the nerve being treated to address pain after amputation.
  • The person has a mental health condition (such as schizophrenia, paranoia, or psychosis), or has language difficulties or reluctance that make it hard to understand what taking part in the study involves.
  • The person is already taking part in another clinical trial that the treating doctor considers could negatively affect participation in this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Max Ortiz Catalan, PhD, Prometei Pain Rehabilitation Center

Phone: +46708461065

Australian sites

Dandenong Hospital, Monash Health, Melbourne,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Prometei Pain Rehabilitation Center
Registry
ClinicalTrials.gov
Start date
20 June 2023
Est. completion
1 June 2026

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇨🇱 Chile 🇮🇹 Italy 🇸🇪 Sweden 🇬🇧 United Kingdom 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Residual limb pain intensity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov